Gene therapy for lung cancer using tumor suppressor gene product as molecular target

以抑癌基因产物为分子靶点的肺癌基因治疗

• 批准号: 09670615
• 负责人: SHIMIZU Eiji
• 金额: $ 1.86万
• 依托单位: University of Tokushima
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09670615/
• 关键词: Lung cancer; Oncogene; Tumor suppressor gene; p16, rb; Gene therapy; Chemotherapy; Pleuritis carcinomatosa; Cisplatin; p16; RB; 抗癌剤感受性試験; コロニー形成試験

Treatment of inoperable lung cancer with pericarditis carcinomatosa consists of pleural administration of anticancer agents and/or inflammation-inducing agents, which have not improved the survival of the patients significantly because of poor local control and distant metastasis. Gene therapy for lung cancer using tumor suppressor gene including p53, rb, p16, an alternative of chemoimmunotherapy, which has recently developed in lung cancer, may improve the survival of the inoperable lung cancer patients with pleuritis carcinomatosa. In this study, we examined the basic and preclinical evaluation of rb and p16 in patients with carcinomatous pleural effusion. Under written informed consent, mononuclear cells were isolated from pleural effusion with seven patients with T4 status. Characteristics of patients include five males and two females/median age 72/6 adenocarcinomas and one small cell carcinoma. These samples formed 0-120 colonies per 200,000 mononuclear cells and five of seven patients were evaluable for antitumor

不能手术的肺癌伴癌性心包炎的治疗包括胸腔给药抗癌剂和/或炎症诱导剂，由于局部控制差和远处转移，这些治疗没有显著改善患者的生存率。肺癌基因治疗是近年来发展起来的一种新的化疗免疫治疗方法，应用抑癌基因p53、Rb、p16进行基因治疗，可提高不能手术的肺癌伴癌性胸膜炎患者的生存率。在这项研究中，我们检测了癌性胸腔积液患者中rb和p16的基础和临床前评估。根据书面知情同意书，从7例T4状态患者的胸腔积液中分离单核细胞。患者特征包括5名男性和2名女性/中位年龄72/6例腺癌和1例小细胞癌。这些样本每200，000个单核细胞形成0-120个集落，7名患者中有5名可评价抗肿瘤活性。

项目成果

Houchi H,et al: "Endothelin-1 stimulatese sodium-dependent calcium efflux from bovine adrenal chromaffin cells in culture." Int J Oncol. 12. 55-60 (1998)

Houchi H 等人：“Endothelin-1 刺激培养物中牛肾上腺嗜铬细胞的钠依赖性钙流出。”

Yamamoto,T., Shimizu,E., Masuda,N., Takada,M.Sone,S.: "RB protein status and chemosensitivity in non-small cell lung cancers" Oncol.Rep.5. 447-451 (1997)

Yamamoto,T.、Shimizu,E.、Masuda,N.、Takada,M.Sone,S.：“非小细胞肺癌中的 RB 蛋白状态和化疗敏感性”Oncol.Rep.5。

Kondo K,et al: "High frequency expressions of CD44 standard and variant forms in non-small cell lung cancers,but not in small cell lung cancers." J Surg Oncol. 69. 128-136 (1998)

Kondo K 等人：“CD44 标准型和变异型在非小细胞肺癌中高频表达，但在小细胞肺癌中则不然。”

清水英治他: "内科学書、島田 馨編" 中山書店, 4 (1999)

清水英二等：《内科书，岛田薫编》中山书店，4（1999）

Kondo K, Miyoshi T, Hino N, Shimizu E, Masuda N, Takada M, Uyama T andMonden Y: "High frequency expressions of CD44 standard and variant forms in non-small cell lung cancers, but not in small cell lung cancers." J Surg Oncol. 69. 128-136 (1998)

Kondo K、Miyoshi T、Hino N、Shimizu E、Masuda N、Takada M、Uyama T 和 Monden Y：“CD44 标准型和变异型在非小细胞肺癌中高频表达，但在小细胞肺癌中则不然。”